Merck Regroups On Mevacor Switch; Could CUSTOM Analysis Pave The Way?
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck is still pursuing an Rx-to-OTC switch of a 20 mg dose of the cholesterol-lowering therapy Mevacor (lovastatin), according to VP-Global Regulatory & Scientific Affairs Edwin Hemwall, PhD
You may also be interested in...
Merck’s Mevacor Switch Bid Digs Deeper Into Consumers’ Self-Selection
Merck's self-selection study developed to support its latest Mevacor OTC switch application will bolster its bid by providing deeper insight into consumers' selection decisions, the firm says
GSK Gets OTC Mevacor U.S. Marketing Rights In Agreement With Merck
GlaxoSmithKline will have exclusive U.S. marketing rights for what would be a first nonprescription statin, pending FDA approval of Merck's Rx-to-OTC switch application for its Mevacor cholesterol-lowering drug
Merck’s Mevacor Returns For OTC Switch Consideration
Merck is in discussions with potential marketing partners for its third Rx-to-OTC switch attempt for the statin Mevacor, as the date approaches for an FDA advisory committee review of the drug